Skip to main content

Table 1 Overall incidence of aberrancies in common T-cell markers in tumor cells of MF and SS.

From: A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy

Aberrancy

CD3

CD4

CD5*

CD7

CD8

CD26

CD45*

TCR*

% of cases

34%

54%

25%

61%

5%

86%

40%

31%

cases tested

15/44

24/44

5/20

27/44

2/44

38/44

4/10

6/19

  1. *Markers tested on only a subset of cases.